Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase
| Autor: | Alan M. Diamond, Soumen Bera, Emily N. Reinke |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
Antioxidant Time Factors medicine.medical_treatment Blotting Western Antineoplastic Agents Biology Gene Expression Regulation Enzymologic chemistry.chemical_compound hemic and lymphatic diseases Cell Line Tumor Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans neoplasms chemistry.chemical_classification Reverse Transcriptase Polymerase Chain Reaction Superoxide Dismutase Imatinib Hematology Glutathione medicine.disease Manganese Superoxide Dismutase Gene Expression Regulation Neoplastic Oncology chemistry Cell culture Enzyme Induction Immunology Cancer research Imatinib Mesylate Selenoprotein Tyrosine kinase Chronic myelogenous leukemia medicine.drug |
| Zdroj: | Leukemialymphoma. 56(4) |
| ISSN: | 1029-2403 |
| Popis: | The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant selenoprotein glutathione peroxidase-1 (GPx-1) was induced by imatinib in both patient samples and cultured cells. Here, we extend these findings to demonstrate that the treatment of CML cell lines, but not non-CML cells, results in an approximately four-fold increase in the levels of another important antioxidant protein, manganese superoxide dismutase (MnSOD), without altering the steady state levels of the corresponding transcript. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|